SYLVATICA BIOTECH INC — Department of Defense SBIR Phase II: DHP15-013
SYLVATICA BIOTECH INC — SBIR Phase II award from Department of Defense.
- Amount
- $1,549,604
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- DHP15-013
- Solicitation
- 15.1
- NAICS
- —
- Place of performance
- NY
- Period
- 2021-04-03 → 2022-09-07
Description
Initially, our technology and partnerships enable the preservation of good, but otherwise untransplanted, extended criteria donor livers as onâÂÂdemand, offâÂÂtheâÂÂshelf, backâÂÂup organs to save both civilian and service members patients lives27–32 where there are no options than often near certain death, and hence the FDA path also is attractive (see Transition Plan and Letters). Through a strategic partnership with ATCC (the premier global biological materials provider, with distribution in over 150 countries and the largest culture collection in the world), we also near term use the technology to make significant numbers of human hepatocyte cells available for transplantation, drug discovery, toxicology, tissue engineering, and bioartificial liver devices. In extension, the approach is also horizontally translatable to VCA and other key organ and tissues systems (and we already have initial funding in place to do so in VCA, kidney and heart transplantation).